12 years' median follow up (MFU) of BIG 1-98: Adjuvant letrozole, tamoxifen and their sequence for postmenopausal women with endocrine responsive early breast cancer

被引：0
|
作者：
Thuerlimann, B. [1 ,2 ]
Giobbie-Hurder, A.
Colleoni, M.
Jensen, M-B
Ejlertsen, B.
de Azambuja, E.
Neven, P.
Lang, I.
Gladieff, L.
Bonnefoi, H.
Harvey, V. J.
Spazzapan, S.
Tondini, C.
Price, K.
Piccart-Gebhart, M.
Regan, M. M.
Gelber, R. D.
Coates, A. S.
Goldhirsch, A.
机构：
[1] Int Breast Canc Study Grp, Bern, Switzerland
[2] BIG 1 98 Collaborat Grp, Bern, Switzerland
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P2-09-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-09-05
引用
收藏
页数：3
相关论文
共 50 条
  • [31] ESR1 and ESR2 polymorphisms in BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence for early breast cancer.
    Bouzyk, M.
    Gray, K. P.
    Regan, M. M.
    Pagani, O.
    Tang, W.
    Kammler, R.
    Maibach, R.
    Viale, G.
    Dell'Orto, P.
    Thurlimann, B. J. K.
    Hitre, E.
    Lyng, M.
    Ditzel, H. J.
    Neven, P.
    MacGrogan, G.
    Price, K. N.
    Gelber, R. D.
    Coates, A. S.
    Goldhirsch, A.
    Leyland-Jones, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Central Review of ER, PgR and HER2 in BIG 1-98 Evaluating Letrozole vs. Letrozole Followed by Tamoxifen vs. Tamoxifen Followed by Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer
    Viale, G.
    Regan, M. M.
    Dell'Orto, P.
    Mastropasqua, M. G.
    Rasmussen, B. B.
    MacGrogan, G.
    Braye, S.
    Orosz, Z.
    Giobbie-Hurder, A.
    Neven, P.
    Knox, F.
    Oehlschlegel, C.
    Thuerlimann, B.
    Coates, A. S.
    Goldhirsch, A.
    CANCER RESEARCH, 2009, 69 (24) : 504S - 504S
  • [33] BIG 1-98: A randomized double-blind phase III study comparing letrozole and tamoxifen given in sequence vs. alone as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.
    Mouridsen, H. T.
    Keshaviah, A.
    Mauriac, L.
    Forbes, J.
    Paridaens, R.
    Castiglione-Gertsch, M.
    Gelber, R.
    Smith, I.
    Thuerlimann, B.
    Goldhirsch, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 10S - 10S
  • [34] Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer
    Giobbie-Hurder, Anita
    Price, Karen N.
    Gelber, Richard D.
    CLINICAL TRIALS, 2009, 6 (03) : 272 - 287
  • [35] Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer:: BIG 1-98
    Viale, Giuseppe
    Regan, Meredith M.
    Maiorano, Eugenio
    Mastropasqua, Mauro G.
    Dell'Orto, Patrizia
    Rasmussen, Birgitte Bruun
    Raffoul, Johnny
    Neven, Patrick
    Orosz, Zsolt
    Braye, Stephen
    Oehlschlegel, Christian
    Thuerlimann, Beat
    Gelber, Richard D.
    Castiglione-Gertsch, Monica
    Price, Karen N.
    Goldhirsch, Aron
    Gusterson, Barry A.
    Coates, Alan S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 3846 - 3852
  • [36] Cost effectiveness analysis of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive breast cancer
    Hashem, I.
    Al-Sherbini, M.
    El-Bary, N. Abd
    Swiha, M.
    BREAST, 2009, 18 : S78 - S78
  • [37] Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole
    Viale, Giuseppe
    Giobbie-Hurder, Anita
    Regan, Meredith M.
    Coates, Alan S.
    Mastropasqua, Mauro G.
    Dell'Orto, Patrizia
    Maiorano, Eugenio
    MacGrogan, Gaetan
    Braye, Stephen G.
    Oehlschlegel, Christian
    Neven, Patrick
    Orosz, Zsolt
    Olszewski, Wojciech P.
    Knox, Fiona
    Thuerlimann, Beat
    Price, Karen N.
    Castiglione-Gertsch, Monica
    Gelber, Richard D.
    Gusterson, Barry A.
    Goldhirsch, Aron
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) : 5569 - 5575
  • [38] COST-EFFECTIVENESS OF LETROZOLE AND OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER USING UPDATED SURVIVAL DATA FROM THE BIG 1-98 AND ATAC TRIALS: A UK PERSPECTIVE
    Karnon, J.
    Kaura, S.
    VALUE IN HEALTH, 2010, 13 (07) : A264 - A264
  • [39] Endocrine Effects of Adjuvant Letrozole Compared With Tamoxifen in Hormone-Responsive Postmenopausal Patients With Early Breast Cancer: The HOBOE Trial
    Rossi, Emanuela
    Morabito, Alessandro
    Di Rella, Francesca
    Esposito, Giuseppe
    Gravina, Adriano
    Labonia, Vincenzo
    Landi, Gabriella
    Nuzzo, Francesco
    Pacilio, Carmen
    De Maio, Ermelinda
    Di Maio, Massimo
    Piccirillo, Maria Carmela
    De Feo, Gianfranco
    D'Aiuto, Giuseppe
    Botti, Gerardo
    Chiodini, Paolo
    Gallo, Ciro
    Perrone, Francesco
    de Matteis, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3192 - 3197
  • [40] Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer
    Buechler, Steven A.
    Gray, Kathryn P.
    Gokmen-Polar, Yesim
    Willis, Scooter
    Thuerlimann, Beat
    Kammler, Rosita
    Viale, Giuseppe
    Leyland-Jones, Brian
    Badve, Sunil S.
    Regan, Meredith M.
    JNCI CANCER SPECTRUM, 2019, 3 (04)
12345